Sökning: onr:"swepub:oai:gup.ub.gu.se/298885" >
Delta NT-proBNP pre...
Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
-
- Andersson, Anton E (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
- Linderholm, Barbro, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
- Giglio, Daniel, 1977 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
(creator_code:org_t)
- 2021
- 2021
- Engelska.
-
Ingår i: Acta oncologica (Stockholm, Sweden). - 1651-226X. ; 60:4, s. 475-481
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Overall survival has improved significantly in patients with human epidermal growth receptor 2 (HER2)-positive breast cancer due to the use of the monoclonal antibody trastuzumab blocking HER2. However, patients may develop trastuzumab-induced cardiotoxicity (TIC) leading to congestive heart failure. Here we assessed whether analysing NT-proBNP and assessment of electrocardiography (ECG) could detect TIC during trastuzumab therapy.One hundred thirty-six patients undergoing adjuvant, neoadjuvant or palliative chemotherapy and HER2 blockade for HER2-positive breast cancer were prospectively assessed with echocardiography, ECG and N-terminal - pro hormone B-type natriuretic peptide (NT-proBNP) testing at baseline and at 6 and 12months of trastuzumab therapy. TIC was defined as a left ventricular ejection fraction (LVEF) of less than 50% and a decline from baseline of ≥10 units.Six patients developed TIC under 12months of trastuzumab therapy (incidence 4.4%). NT-proBNP increased from 198.8±64.0pg/ml to 678.7±132.4pg/ml (p<.05) in TIC patients. With a cut-off point of 276.5pg/ml for NTproBNP and increase in NT-proBNP by 75.8pg/ml from baseline the sensitivity was 100% and the specificity 95% to detect TIC. Compared with controls, TIC patients were older (68.3±1.1years and 56.2±1.4years, respectively; p<.01), had more often diabetes mellitus (OR = 63.5, 95% CI: 5.63-915, p<.01) and atrial fibrillation (OR = 12.3; 95% CI: 1.89-74.62; p<.05) and had lower baseline LVEF (57.1±1.4% and 61.4±0.3%, respectively; p<.001). Abnormal ECGs were common in patients developing TIC.Measuring changes in NTproBNP may be used to monitor patients for TIC under trastuzumab therapy. Patients with a cardiovascular risk profile are more at risk of developing TIC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- oncology
- cancer
- onkologi
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas